Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 10, 1298 - 1299 (2004)
doi:10.1038/nm1204-1298
Cancer drug discovery: the wisdom of imprecision
Andrei V Gudkov1
- The author is in the Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, USA. e-mail: gudkov@ccf.org
Abstract
Drug discovery is either an exact business that is based on detailed knowledge of target structure or it is a fishing expedition that uncovers new drugs through screening of random compounds for their biological effect on target function. Isolation of a new p53 activator with anticancer properties strengthens the reputation of this second approach (pages 1321–1328).
Most human cancers inactivate the function of the tumor suppressor p53 during their progression. There is good reason: p53 blocks proliferation of or eliminates cells that have experienced DNA stress or have deregulated proto-oncogenes.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Optical coherence tomography for ultrahigh resolution in vivo imagingNature Biotechnology Research (01 Nov 2003)
Enzymatic synthesis of antithrombin III?binding heparan sulfate pentasaccharideNature Biotechnology Research (01 Nov 2003)
Selectivity of Pyripyropene Derivatives in Inhibition toward Acyl-CoA:cholesterol Acyltransferase 2 IsozymeThe Journal of Antibiotics Original Article
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transferNature Immunology Article (01 Oct 2001)
See all 8 matches for Research